UCERIS: Power patients can handle
UCERIS features MMX® technology, which is designed to target delivery of budesonide throughout the full length of the colon.1 Budesonide is a highly potent, locally acting corticosteroid that is rapidly metabolized; therefore, it must be delivered to its desired site of action for optimal effect.
MMX® technology is designed to target delivery of budesonide throughout the full length of the colon.1View Pharmacoscintigraphic Image
UCERIS tablets dissolve at a pH ≥7.0. During this process, the pill matrix expands and forms a hydrogel.
Budesonide has been detected by scintigraphic imaging in the ascending colon between 4 and >24 hours after dosing. The medication is then absorbed into the body and subject to a high first-pass metabolism (80-90%), thereby minimizing side effects.
When transferring patients from glucocorticosteroid treatment with higher systemic effects to glucocorticosteroids with lower systemic effects, such as UCERIS, taper patients slowly to avoid withdrawal effects.
In a pooled analysis of 2 Phase III clinical trials comparing UCERIS versus placebo, 3 times more patients taking UCERIS achieved clinical and endoscopic remission.2*
Patients with moderate to severe liver disease should be monitored for increased signs and/or symptoms of hypercorticism.
Adverse Events Experienced by ≥2% of Patients in 2 Clinical Trials
UCERIS 9 mg (n=255)
|Headache||29 (11.4)||27 (10.5)|
|Nausea||13 (5.1)||11 (4.3)|
|Decreased blood cortisol||11 (4.3)||1 (0.4)|
|Upper abdominal pain||10 (3.9)||5 (1.9)|
|Fatigue||8 (3.1)||5 (1.9)|
|Flatulence||6 (2.4)||5 (1.9)|
|Abdominal distention||6 (2.4)||2 (0.8)|
|Acne||6 (2.4)||5 (1.9)|
|Urinary tract infection||5 (2.0)||1 (0.4)|
|Arthralgia (joint pain)||5 (2.0)||4 (1.6)|
|Constipation||5 (2.0)||2 (0.8)|
UCERIS has a safety profile that offers confidence. In the same analysis described above, there were no clinically significant differences in glucocorticoid-related side effects between UCERIS and placebo at 8 weeks—10.2% vs 10.5%, respectively.3
Convenient, once-daily dosing
UCERIS 9-mg tablets are to be taken once daily in the morning for up to 8 weeks.
|Strength||NDC Number||Package Size|
|UCERIS 9 mg||68012-309-30||30 tablets|
Most eligible patients with commercial insurance will pay only $25 for UCERIS.†Learn more
*CORE study design: Two randomized, double-blind, placebo-controlled studies were conducted in a total of 899 adult patients with active, mild to moderate UC (UCDAI: ≥4 and ≤10 at entry). The primary endpoint was induction of combined clinical and endoscopic remission (defined as a UCDAI score of ≤1, with scores of 0 for both rectal bleeding and stool frequency, normal mucosa with no friability on endoscopy, and a ≥1-point reduction in the EI score) after 8 weeks of treatment.
†Some restrictions apply. Salix Pharmaceuticals, Inc. reserves the right to modify or cancel this offer at any time.